20-F: Immutep Advances LAG-3 Pipeline Amid Rising R&D Costs

Immutep Limited reported increased net losses for fiscal year 2025 due to expanded clinical trial activities, while advancing its lead LAG-3 immunotherapy candidates through late-stage development and securing new patents.

Summary

• Net loss for fiscal year 2025 increased to A$61.4 million, up from A$42.7 million in fiscal year 2024, primarily due to higher clinical trial expenses.
• Research & Development and Intellectual Property expenses rose significantly to A$61.41 million in fiscal year 2025 from A$41.55 million in fiscal year 2024.
• Total other income increased to A$10.3 million in fiscal year 2025, driven by A$5.3 million in interest income and A$4.13 million in French R&D grant income.
• Cash and cash equivalents stood at A$67.41 million as of June 30, 2025, with an additional A$62.28 million in short-term investments, totaling A$129.69 million in liquidity.
• The pivotal TACTI-004 Phase III trial for 1st line NSCLC commenced, with the first patient dosed in March 2025, and Merck & Co. supplying KEYTRUDA at no cost.
• The TACTI-003 Phase IIb trial in 1st line HNSCC completed enrollment, showing encouraging efficacy in PD-L1 negative patients (35.5% ORR, 9.7% CR, median OS not reached) and favorable safety.
• The AIPAC-003 Phase II/III trial for metastatic breast cancer reported a 50% ORR and 100% DCR in its safety lead-in, with the FDA agreeing on 30mg as the optimal biological dose for efti.
• The investigator-initiated EFTISARC-NEO Phase II trial in soft tissue sarcoma met its primary endpoint, showing significant tumor hyalinization/fibrosis (median 50%) with a triple combination therapy.
• The INSIGHT-003 Phase I trial for solid tumors demonstrated robust efficacy (71.4% ORR, 90.5% DCR) and excellent survival data (median OS 32.9 months) with a triple combination therapy.
• Immutep was granted 17 new patents in fiscal year 2025, including 7 for efti, 6 for IMP761, and 4 for IMP701, strengthening its intellectual property portfolio.
• The remaining 6.25% of convertible notes (A$1.1 million) and 847,600 warrants were converted/net settled into ordinary shares on July 18, 2025.

Sentiment

Score: 6

Explanation: While financial losses increased and cash burn accelerated, the company made significant clinical progress in multiple late-stage trials, secured new patents, and has sufficient liquidity for the near term. The increased R&D spend is a necessary investment for a development-stage biotech, and positive clinical data provides a strong foundation for future value creation, despite the current financial performance.

Positives

• Significant progress in late-stage clinical trials, including the commencement of the pivotal TACTI-004 Phase III trial for 1st line NSCLC with Merck & Co. collaboration.
• Encouraging efficacy and safety data from TACTI-003 Phase IIb in 1st line HNSCC, particularly in PD-L1 negative patients, with FDA support for further development in this segment.
• Positive initial safety and efficacy data from AIPAC-003 Phase II/III in metastatic breast cancer, including a 50% ORR and 100% DCR in the safety lead-in.
• EFTISARC-NEO Phase II trial met its primary endpoint, showing significant pathological responses in soft tissue sarcoma, expanding efti's potential application.
• INSIGHT-003 Phase I trial reported excellent long-term survival data (median OS 32.9 months) and high response rates for its triple combination therapy.
• Successful scale-up of efti manufacturing to 2,000L commercial scale, securing supply for late-stage clinical trials and potential commercialization.
• Strengthened intellectual property with 17 new patents granted in fiscal year 2025 across key product candidates (efti, IMP761, IMP701).
• Initiation of the first-in-human Phase I study for IMP761, a novel LAG-3 agonist for autoimmune diseases, showing significant T cell suppression and favorable safety.
• Increased interest income of A$5.3 million and grant income of A$4.13 million contributed to higher other income in fiscal year 2025.

Negatives

• Net loss increased to A$61.4 million in fiscal year 2025, indicating a higher cash burn rate compared to the previous year.
• Research & Development expenses significantly increased by A$19.86 million, reflecting the rising costs of advancing multiple clinical trials.
• Net cash used in operating activities increased to A$62.05 million, indicating a substantial increase in operational cash outflow.
• Experienced a net loss on foreign exchange of A$1.53 million in fiscal year 2025, a reversal from a net gain in the prior year.
• IMP731, previously licensed to GSK, was returned to Immutep in 2024, requiring the company to explore new development and commercialization options for this asset.
• The TACTI-003 Cohort A data in PD-L1 positive HNSCC patients was difficult to interpret due to imbalances in prognostic markers, potentially obscuring clear conclusions for this subgroup.

Risks

• History of operating losses and uncertainty in achieving or maintaining future profitability.
• No medicinal products approved for commercial sale and no consistent material revenue, dependent on future success of product candidates.
• Anticipated increase in expenses for clinical trials and regulatory applications, requiring additional funding that may not be available on acceptable terms.
• Potential for dilution from future equity fundraising or restrictive covenants from debt-based funding.
• Difficulty enrolling patients in clinical trials or patient discontinuation, which could delay or prevent completion of trials.
• Inability to successfully develop related diagnostics for therapeutic product candidates, potentially delaying marketing approval or limiting commercial potential.
• Ongoing research and development efforts may not successfully develop any product candidate, impacting business strategy.
• Positive preclinical results are not necessarily predictive of clinical trial success, leading to potential setbacks.
• Risks associated with acquisitions, including integration difficulties, diversion of management attention, and potential loss of key personnel.
• Ongoing and future clinical trials may not show sufficient safety or efficacy to obtain regulatory approvals.
• Limited manufacturing experience and dependence on third parties for manufacturing, leading to risks of supply limitations, interruptions, or quality issues.
• Reliance on collaborations and strategic alliances exposes the company to risks of partners not devoting sufficient resources, financial difficulties, or termination of agreements.
• Disagreements with collaborators over intellectual property rights or payment terms could result in costly litigation and reputational damage.
• Inability to retain key personnel and cultivate academic/scientific collaborations could jeopardize research and development efforts.
• Lack of market acceptance by physicians, patients, and the medical community, even if products are approved.
• Intense competition from other pharmaceutical and biotechnology companies with greater resources and experience.
• Healthcare insurers and other organizations may not pay for products or impose reimbursement limits, affecting future revenues.
• Exposure to product liability claims from testing, marketing, and sale of therapeutic products.
• Risks related to handling, storage, or disposal of biological and hazardous materials.
• Adverse impact on business, non-clinical studies, and clinical trials from war, pandemics, or macroeconomic factors.
• Internal computer systems or those of contractors may fail or suffer security breaches, disrupting product development.
• Failure to obtain and maintain patent protection or orphan drug designation/status, or challenges to existing intellectual property rights.
• Intellectual property rights of third parties could require costly litigation or licenses.
• Reliance on third parties requires sharing trade secrets, increasing risk of disclosure or misappropriation.
• Changes in patent laws or jurisprudence could diminish the value of patents.
• Difficulties in protecting intellectual property in certain jurisdictions.
• Stock price volatility due to various factors, including clinical trial results, regulatory actions, and market conditions.
• Significant cost and administrative burden from auditor attestation requirements under Sarbanes-Oxley Act.
• Potential classification as a passive foreign investment company (PFIC) for U.S. shareholders, leading to adverse tax rules.
• No intention to pay dividends in the foreseeable future, meaning investment return depends on share price appreciation.
• Currency fluctuations may adversely affect the price of ADSs relative to ordinary shares.
• Requirements of being a public company may strain resources and divert management attention.
• Listing on multiple exchanges may adversely impact liquidity and create arbitrage opportunities.
• Australian takeover laws may discourage takeover offers or large share acquisitions.
• Rights as an ADS holder are governed by U.S. law, while shareholder rights are governed by Australian law, with potential differences.
• Difficulties in effecting service of process or enforcing judgments obtained in the United States due to Australian incorporation.
• Following home country corporate governance practices instead of certain NASDAQ requirements.
• Exposure to differing legal and tax laws in multiple jurisdictions, including complex transfer pricing rules in Australia.

Future Outlook

The company anticipates continued substantial and increasing losses for the foreseeable future as it expands research and development activities and progresses product candidates into later stages of development. Current cash and cash equivalents are expected to fund operations until at least the end of calendar year 2026. Future capital requirements are difficult to forecast and will depend on the costs and timing of clinical trials, regulatory approvals, and commercialization efforts. The company will explore opportunities in head and neck cancer development (CPS<1) with stakeholders and partners, while its main focus remains the pivotal TACTI-004 Phase III trial in lung cancer. Additional data updates from the INSIGHT-003 trial are expected to be presented at medical conferences in 2025 and beyond. Clinical trials for IMP761 are anticipated to continue with higher single ascending dose levels.

Management Comments

• Management is monitoring the impact of inflation on operations and financial condition and continues to carefully negotiate prices for required services and supplies.
• The Board believes the company is not of a size, nor are its financial affairs of such complexity, to justify the establishment of a Nomination Committee of the Board of Directors.
• The company endeavors to achieve simplicity and transparency in remuneration design, whilst also balancing competitive market practices in France, Germany, and Australia.

Industry Context

Immutep operates in the highly competitive immuno-oncology and autoimmune disease subsectors of the biopharma industry. The company is a pioneer in LAG-3 related immunotherapies, a field with significant industry interest due to the therapeutic benefits of checkpoint inhibitors. The strategy of combining efti with anti-PD-1/PD-L1 therapies aligns with the industry trend of exploring combination treatments to enhance anti-tumor immune responses and overcome resistance. The development of IMP761 as a LAG-3 agonist for autoimmune diseases positions Immutep in a growing area targeting underlying causes of these disorders. The shift in standard of care for urothelial carcinoma highlights the dynamic nature of the industry and the need for adaptive clinical development strategies.

Comparison to Industry Standards

• TACTI-003 Cohort B (PD-L1 negative HNSCC) results (35.5% ORR, 9.7% CR) compared favorably to a historical control of 5.4% ORR and 0% CR from anti-PD-1 monotherapy in 1L HNSCC patients with a CPS <1.
• INSIGHT-003 triple combination therapy achieved a 70.6% response rate in PD-L1 TPS <50% NSCLC patients, which compares favorably with results from an independent registrational trial of anti-PD-1 and doublet chemotherapy (40.8% response rate) in a similar patient population.
• EFTISARC-NEO trial's median 50% tumor hyalinization/fibrosis significantly exceeded historical median 15% from standard radiotherapy alone in resectable soft tissue sarcoma patients.

Management Changes

Corporate Governance

Legal Proceedings

• Not involved in any legal or arbitration proceedings, including those relating to bankruptcy, receivership or similar proceedings and those involving any third party, which may have, or have had in the recent past, significant effects on financial position or profitability.
• Not involved in any governmental proceedings pending or known to be contemplated.

Related Party Transactions

• No transactions occurred with related parties for fiscal year ended June 30, 2025, other than the payment of Directors fees.
• No trade receivables from or trade payables due to related parties at the reporting date.
• No loans to or from related parties at the reporting date.

Stakeholder Impact

• **Shareholders:** Increased net losses and cash burn may negatively impact short-term share price, but significant clinical progress and IP strengthening could drive long-term value. Dilution from future capital raises is a potential concern. ADS holders have different rights than ordinary shareholders.
• **Employees:** Increased R&D activities suggest continued employment and potential growth opportunities. Executive Incentive Plan aims to attract and retain key talent through performance rights. Changes in senior management may affect team dynamics.
• **Customers (Future):** Successful clinical trial outcomes and regulatory approvals for product candidates like efti and IMP761 could lead to new treatment options for cancer and autoimmune diseases, benefiting patients.
• **Suppliers/Contractors:** Continued reliance on third-party manufacturers and CROs for clinical trials and manufacturing provides ongoing business for these partners, but also exposes the company to their operational risks.
• **Creditors:** The company's liquidity position (A$129.69 million) is expected to fund operations until at least the end of calendar year 2026, providing a reasonable buffer for current liabilities.

Next Steps

• Continue to progress the pivotal TACTI-004 Phase III trial for 1st line NSCLC, with ongoing site activation and patient enrollment.
• Explore opportunities for further development in head and neck cancer (CPS<1) with stakeholders and partners, following encouraging TACTI-003 Cohort B data.
• Continue with single ascending dose levels of 2.5, 7, and 14 mg/kg in the IMP761 Phase I study.
• Examine data returned from GSK for IMP731 and explore options for further developing and commercializing this asset.
• Present detailed results from the EFTISARC-NEO Phase II trial at a future medical meeting.
• Provide additional data updates from the INSIGHT-003 trial at medical conferences in 2025 and beyond.
• Revisit the trial protocol, informed consent form (ICF), and regulatory submissions for INSIGHT-005 with Merck KGaA to ensure the study remains relevant for metastatic urothelial carcinoma.
• Dr Russell Howard will be issued 1,573,646 performance rights, subject to shareholder approval at the 2025 Annual General Meeting, with tranches vesting annually from December 1, 2025, to December 1, 2028.
• Mr Pete Meyers will stand for re-election at the Company's Annual General Meeting in 2025.

Key Dates

Recommendation

Immutep is a development-stage biotechnology company with a strong focus on advancing its LAG-3 pipeline, particularly efti, through pivotal clinical trials. While the increased net loss and cash burn in FY2025 are concerning, they reflect necessary investments in late-stage R&D, which is typical for companies in this phase. The positive clinical data from TACTI-003, AIPAC-003, EFTISARC-NEO, and INSIGHT-003, coupled with the commencement of the Phase III TACTI-004 trial and new patent grants, indicate significant progress towards potential commercialization. The company's current liquidity position is adequate for the next 18 months. However, the inherent risks of drug development, the need for future capital raises, and the competitive landscape warrant a 'hold' recommendation. Investors should monitor upcoming clinical data, regulatory milestones, and future financing activities closely, as these will be critical determinants of long-term value.

Keywords

Immutep, LAG-3, Immunotherapy, Cancer, Autoimmune Disease, Eftilagimod Alfa, Efti, IMP321, TACTI-004, NSCLC, TACTI-003, HNSCC, AIPAC-003, Metastatic Breast Cancer, IMP761, Clinical Trials, Biotechnology, Pharmaceutical, SEC Filing, 20-F, Oncology, Drug Development, Biologics, Patents, R&D, NASDAQ, ASX